Form 4 Filing for Axsome Therapeutics, Inc. - Maizel Ari

This filing details a Form 4 submission by Ari Maizel, Chief Commercial Officer of Axsome Therapeutics, Inc. On April 21, 2026, Maizel acquired 7,224 Performance Stock Units (PSUs) with a transaction value of $0. These PSUs are contingent on the achievement of certain sales and commercial launch milestones, and are subject to Maizel's continued service. Each PSU represents the right to receive one share of Axsome Therapeutics' common stock. Following this transaction, Maizel holds 7,224 shares of common stock underlying the PSUs. The filing was signed on April 23, 2026.